Y-MABS THERAPEUTICS INC's ticker is YMAB and the CUSIP is 984241109. A total of 115 filers reported holding Y-MABS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $7 | -100.0% | 1,443 | 0.0% | 0.00% | – |
| Q3 2022 | $21,000 | -4.5% | 1,443 | 0.0% | 0.00% | – |
| Q2 2022 | $22,000 | +22.2% | 1,443 | 0.0% | 0.00% | – |
| Q1 2022 | $18,000 | -21.7% | 1,443 | 0.0% | 0.00% | – |
| Q4 2021 | $23,000 | -43.9% | 1,443 | 0.0% | 0.00% | – |
| Q3 2021 | $41,000 | -16.3% | 1,443 | 0.0% | 0.00% | – |
| Q2 2021 | $49,000 | +14.0% | 1,443 | 0.0% | 0.00% | – |
| Q1 2021 | $43,000 | -39.4% | 1,443 | 0.0% | 0.00% | – |
| Q4 2020 | $71,000 | +29.1% | 1,443 | 0.0% | 0.00% | – |
| Q3 2020 | $55,000 | -11.3% | 1,443 | 0.0% | 0.00% | – |
| Q2 2020 | $62,000 | +63.2% | 1,443 | 0.0% | 0.00% | – |
| Q1 2020 | $38,000 | -15.6% | 1,443 | 0.0% | 0.00% | – |
| Q4 2019 | $45,000 | +40.6% | 1,443 | +4.3% | 0.00% | – |
| Q2 2019 | $32,000 | – | 1,383 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | 216,916 | $6,191,000 | 3.86% |
| Sofinnova Investments, Inc. | 2,194,278 | $62,625,000 | 3.71% |
| MPM BioImpact LLC | 452,970 | $12,928,000 | 2.00% |
| Soleus Capital Management, L.P. | 265,700 | $7,583,000 | 1.18% |
| ASHFORD CAPITAL MANAGEMENT INC | 452,110 | $12,903,000 | 1.17% |
| ORACLE INVESTMENT MANAGEMENT INC | 315,642 | $9,008,000 | 1.12% |
| First Light Asset Management, LLC | 577,663 | $16,487,000 | 1.09% |
| Lombard Odier Asset Management (Switzerland) SA | 352,839 | $10,070,000 | 0.62% |
| Cormorant Asset Management, LP | 500,000 | $14,270,000 | 0.58% |
| Artal Group S.A. | 400,000 | $11,416,000 | 0.26% |